IMMX

+ Watchlist + Portfolio

Immix Biopharma, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $13.19
52-Week Range: $1.94 – $13.20
Market Cap: $936.86M
P/E (TTM): —
EPS (TTM): -0.88
Dividend Yield: —

Advanced Metrics

Price/Book: 4.11
PEG Ratio: —
Return on Equity: -34.18%
Return on Assets: -20.52%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 25.13
Debt/Equity: 0.00
Total Debt: $1.00M
Free Cash Flow: $-25.39M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $712.50M

IMMX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$4.20M	$8.74M	$11.29M	$16.26M
Selling, General & Admin	$4.02M	$7.41M	$11.38M	$13.70M
Operating Expenses	$8.22M	$16.14M	$22.67M	$29.96M
Operating Income	-$8.22M	-$16.14M	-$22.67M	-$29.96M
EBITDA	-$8.22M	-$16.14M	-$22.56M	-$29.59M
Pretax Income	-$8.22M	-$15.57M	-$21.66M	-$29.40M
Income Tax	$10.27K	$26.41K	$41.04K	$37.72K
Net Income	-$8.23M	-$15.43M	-$21.61M	-$29.44M
Diluted EPS	-0.59	-0.89	-0.76	-0.89
Diluted Shares	13.89M	17.34M	28.29M	32.97M

IMMX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$13.44M	$17.51M	$17.68M	$93.93M
Receivables	$255.71K	$1.17M	$1.97M	$0.00
Current Assets	$14.90M	$19.79M	$20.20M	$101.24M
Total Assets	$14.91M	$19.93M	$22.95M	$104.84M
Current Liabilities	$1.27M	$3.72M	$8.69M	$10.11M
Total Debt	—	$0.00	$1.07M	$1.07M
Total Liabilities	$1.75M	$3.72M	$9.70M	$11.04M
Retained Earnings	-$37.99M	-$53.41M	-$75.02M	-$104.46M
Shareholders' Equity	$13.16M	$16.41M	$13.25M	$93.80M
Working Capital	$13.62M	$16.07M	$11.51M	$91.13M

IMMX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$7.41M	-$11.37M	-$14.60M	-$23.93M
Capital Expenditure	—	-$52.09K	-$1.18M	-$732.92K
Free Cash Flow	-$7.41M	-$11.42M	-$15.77M	-$24.66M
Depreciation & Amortisation	$2.13K	$5.47K	$115.39K	$364.50K
Stock-Based Compensation	$624.07K	$2.57M	$3.02M	$2.44M
Investing Cash Flow	$0.00	-$52.09K	-$1.18M	-$7.21M
Financing Cash Flow	$3.23M	$15.46M	$15.95M	$107.39M
Share Repurchases	-$99.96K	$0.00	—	—
Net Change in Cash	-$4.18M	$4.04M	$175.78K	$76.24M

IMMX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$1.98M	$3.97M	$4.58M	$5.73M	$5.98M
Selling, General & Admin	$2.71M	$2.75M	$3.08M	$5.17M	$4.82M
Operating Expenses	$4.68M	$6.72M	$7.66M	$10.89M	$10.80M
Operating Income	-$4.68M	-$6.72M	-$7.66M	-$10.89M	-$10.80M
EBITDA	-$4.62M	-$6.64M	-$7.53M	-$10.80M	-$10.67M
Pretax Income	-$4.53M	-$6.61M	-$7.58M	-$10.68M	-$10.09M
Income Tax	$9.82K	$8.91K	$7.72K	$11.27K	$0.00
Net Income	-$4.54M	-$6.62M	-$7.59M	-$10.69M	-$10.09M
Diluted EPS	-0.15	-0.22	-0.24	—	-0.18
Diluted Shares	29.70M	29.98M	31.93M	—	55.37M

IMMX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$15.92M	$11.64M	$15.95M	$93.93M	$79.25M
Receivables	$0.00	$0.00	$0.00	$0.00	—
Current Assets	$16.78M	$12.33M	$16.58M	$101.24M	$92.27M
Total Assets	$19.89M	$15.64M	$20.08M	$104.84M	$95.82M
Current Liabilities	$9.31M	$10.01M	$10.85M	$10.11M	$10.54M
Total Debt	$1.06M	$1.04M	$1.11M	$1.07M	$1.04M
Total Liabilities	$10.30M	$10.98M	$11.82M	$11.04M	$11.45M
Retained Earnings	-$79.57M	-$86.19M	-$93.78M	-$104.46M	-$114.55M
Shareholders' Equity	$9.59M	$4.65M	$8.26M	$93.80M	$84.36M
Working Capital	$7.47M	$2.32M	$5.73M	$91.13M	$81.74M

IMMX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$1.69M	-$5.31M	-$5.91M	-$11.03M	-$9.83M
Capital Expenditure	-$67.71K	-$127.63K	-$372.46K	-$165.13K	-$32.49K
Free Cash Flow	-$1.75M	-$5.44M	-$6.28M	-$11.19M	-$9.86M
Depreciation & Amortisation	$59.18K	$79.83K	$134.85K	$90.63K	$130.77K
Stock-Based Compensation	$868.36K	$532.25K	$470.47K	$570.80K	$575.57K
Investing Cash Flow	-$67.71K	-$127.63K	-$372.46K	-$6.65M	-$4.80M
Financing Cash Flow	$0.00	$1.11M	$10.61M	$95.67M	-$37.56K
Net Change in Cash	-$1.75M	-$4.33M	$4.33M	$77.99M	-$14.67M

Market Snapshot

About

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company developing oncology therapies targeting tissue factor and tissue factor pathway inhibitor (TFPI). The company's lead program focuses on treating solid tumors and hematological malignancies through novel mechanisms of action. Immix is advancing multiple candidates through preclinical and clinical development stages. The company's approach aims to address cancers with significant unmet medical needs through innovative targeting of the tissue factor pathway.